CytomX Therapeutics Stock News

CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) --  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that

Biotech penny stocks to watch this week. Are they a buy now?

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategic partnership will see the two compa

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Chau Cheng - Vice President of Investor Relations & Corporate Communications Se

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that 

CytomX Therapeutics Inc (NASDAQ: CTMX) is restructuring its business to prioritize internal investments in its emerging pre-clinical and early clinical pipeline. The company will cut 40% of its wor